Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Rating) – Stock analysts at Wedbush reduced their Q3 2022 EPS estimates for shares of Edgewise Therapeutics in a research report issued on Wednesday, May 11th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($0.38) for the quarter, down from their previous […]
Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Rating) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among […]
Equities research analysts at Royal Bank of Canada began coverage on shares of Edgewise Therapeutics (NASDAQ:EWTX – Get Rating) in a report released on Wednesday, The Fly reports. The firm set an “outperform” rating on the stock. A number of other brokerages also recently issued reports on EWTX. The Goldman Sachs Group started coverage on […]
Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Rating) gapped down prior to trading on Wednesday . The stock had previously closed at $10.78, but opened at $10.38. Edgewise Therapeutics shares last traded at $10.42, with a volume of 200 shares changing hands. A number of research firms have recently commented on EWTX. The Goldman Sachs Group […]
Edgewise Therapeutics (NASDAQ: EWTX – Get Rating) is one of 929 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Edgewise Therapeutics to similar businesses based on the strength of its analyst recommendations, dividends, risk, institutional ownership, earnings, profitability and valuation. Analyst Recommendations This is a […]